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Background: Paraneoplastic leukemoid reaction (PLR) is a well-described entity in which the
white blood cell count expands to greater than 50,000/mm3 in association with malignancy. It is
thought to occur in approximately 10–15% of cancers. Notably, PLR is known to be predictive of
a poor prognosis. Recent work has demonstrated that there may be a relationship between PLR
activated by intratumoral production of granulocyte colony-simulating factor (G-CSF), the RAS/
RAF/MEK pathway and tumorogenesis. Speciﬁcally, activation of the RAS/RAF/MEK pathway is
thought to regulate G-CSF production, which in turn, mediates expansion and mobilization of
cells that produce factors that promote tumor metastasis.
Methods/results: In this report we demonstrate the PLR response to treatment in a patient
with non-small cell lung cancer. Additionally, we demonstrate elevated G-CSF in the patient's
serum 507 pg/ml (0–39.1 pg/ml) and positive staining by immunohistochemistry of G-CSF in the
patient's tumor tissue. Finally, we describe a possible pathway by which this promotes tumor
spread.
Conclusion: Though G-CSF has been traditionally viewed as a prognostic marker, here we
provide evidence that it may be a valuable marker to investigate for treatment response at a
cellular level.
& 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)..03.003
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The presence of leukocytosis associated with solid tumors has
been documented for many decades [1]. The ﬁrst demonstra-
tion that it was the tumor itself producing a colony-stimulating
agent came in 1977 when Asano et al. demonstrated that serial
transplantation of human lung cancer tissue from a patient with
neutrophilia into mice caused neutrophilia in recipient mice as
well [2]. The formal deﬁnition of a leukemoid reaction is a
white blood cell (WBC) count 450,000/mm3 with a predomi-
nance of neutrophil precursors. When this elevation in the WBC
count is associated with malignancy it is termed a paraneo-
plastic leukemoid reaction (PLR) [3]. The differential diagnosis
of leukemoid reaction includes infection, hematologic malig-
nancy, iatrogenic origin (e.g. steroids, growth factors), solid
tumor spread to bone and PLR. Two different case series have
reviewed the frequency of PLR. Granger et al. evaluated 3770
consecutive solid tumor patients and found that, of the 758
patients with extreme leukocytosis, 77 (10%) of these patients
had PLR. Interestingly, only 13 of the 77 patients (17%) had non-
small cell lung cancer (NSCLC), but 41 (53%) patients overall
had tumors involving the lungs [4]. Kasuga et al. evaluated a
series of 227 patients with lung carcinoma and identiﬁed 33
(14.5%) patients with PLR. They also found that 16 patients
showed elevated serum granulocyte colony-simulating factor
(G-CSF) levels with 12 tumors staining positive for G-CSF by
immunohistochemisty (IHC) [5]. Another notable ﬁnding of the
elevated WBC count in these case series and other case reports
is that leukemoid reactions are predictive of a poor prognosis.
In a study by Granger et al., 76% of patients diagnosed with PLR
died within 12 weeks. Other series and case reports have noted
similar prognostic information [5,3].
Here we report the ﬁrst description, to our knowledge, of
non-small cell adenocarcinoma of the lung that evolved during
treatment to have a PLR that was responsive to both systemic
treatment and radiation therapy.Figure 1 Correlation of WBC with anti-neoplastic therapy. WB
also shown. Day number is from the time of diagnosis.2. Case history
A 51-year-old man initially presented with a protracted
period of cough, night sweats, recurrent fevers and weight
loss. He was a lifelong never-smoker and had no signiﬁcant
past medical history and no family history of malignancy.
After several recurrences of pneumonia, imaging studies
ultimately thoracic lymphadenopathy, a mass right hilar
mass, and a superior segment mass. He underwent a
diagnostic CT guided biopsy and a staging PET/CT scan and
was diagnosed with T4N2M0 (stage IIIb) adenocarcinoma of
the lung. At the time of presentation, his WBC count was
12,000/mm3.
He started treatment with weekly carboplatin and pacli-
taxel for ﬁve weeks with concurrent intensity modulated
radiotherapy (IMRT) to 50.4 Gy. During this treatment, his
WBC count was 4300–10,700/mm3. A PET/CT scan 2 months
after initiation of treatment demonstrated osseous progres-
sion. He then began treatment with cisplatin and peme-
trexed. He tolerated this therapy well and had a normal
WBC count (Figure 1, days 0–200). He subsequently started
on pemetrexed maintenance therapy for 2 cycles. After
cycle 2, he began noting right neck/supraclavicular swel-
ling. A PET/CT scan demonstrated worsening of hypermeta-
bolic soft tissue tumor burden, and elevated bone marrow
ﬂuorodeoxyglucose-avidity (FDG). Increased bone marrow
FDG avidity can be seen in reactive marrow responding to
chemotherapy, growth factor, or tumor inﬁltration along
with other less likely processes. Additionally, his WBC count
began rising (Figure 1, days 200–240). The leukocytosis
primarily consisted of neutrophils, although there was a
left-shift with some band neutrophils, metamyelocytes,
myelocytes and promyelocytes present. He was initiated
on a clinical trial of gemcitabine in combination with
MLN8237, a second-generation Aurora A kinase inhibitor
that is thought to act by inhibiting mitosis by acting on theC is expressed as 103/mm3. Anti-neoplastic treatments are
Figure 2 Endobronchial biopsy of patient's right lung mass
demonstrating involvement by NSCLC cells expressing G-CSF.
Representative images (20 magniﬁcation) of hematoxylin and
eosin staining (a) and immunohistochemical staining with anti-
G-CSF antibody (b) are shown. Images are from the same area
of the biopsy. Note brown staining indicating G-CSF expression
in tumor cells, while normal lung tissue without tumor involve-
ment does not stain positive for G-CSF expression (b).
17Paraneoplastic leukemoid reactionmitotic spindle and is predicted to cause cytopenias.
Patients on this trial were not given growth factor support
or glucocorticoid treatment. During this treatment, the
WBC count, which had been rising, normalized after each
cycle but again increased prior to the next cycle. WBC
values during this period are shown in Figure 1 (days 240–
300) and included: Pre-Cycle 1 WBC 35,300/mm3 (91.4%
PMN/bands); Cycle 1 day 12 WBC 9300/mm3 (90.6% PMN/
bands); Pre-Cycle 2 WBC 55,500/mm3 (85% PMN/bands); and
Cycle 2 day 18 WBC 10,400/mm3 (93.3% PMN/bands).
Imaging after cycle 2 demonstrated interval disease pro-
gression in bones and soft tissue. For example, the right
neck lesion noted above increased from 2.8 3 cm to
5.3 4.7 cm. He stopped the clinical trial due to disease
progression. He then received palliative radiation to his
neck lesion (30 Gy over 10 fractions), for tumor related
pain. This temporarily improved his symptoms, however,
with the next imaging study done 21 days after radiation the
lesion had increased to 5.5 6.3 cm.There was a marked
decrease in his WBC count from 94,300/mm3 (96% PMN/
bands with left shift) to 31,100/mm3 (96.1% PMN/bands
with left shift) (Figure 1, days 300–330) during radiation
treatment. After radiation, his WBC count again began to
increase (Figure 1, days 331–340). Following radiation
therapy for local palliation, he enrolled in a clinical trial
of the anti-PD-L1 antibody to address worsening systemic
disease burden, and his WBC count again dropped during
therapy (Figure 1, days 340–360). CT scan of the chest after
his second infusion showed tumor progression in his thoracic
lymph nodes. With all three treatments, which act through
different mechanisms, the patient experienced reduction in
WBC counts after treatment; however, the pace of tumor
cell growth ultimately outpaced any therapeutic beneﬁt.
Due to his progressive and symptomatic disease he elected
to pursue hospice treatment and expired shortly thereafter.
To determine the etiology of the leukocytosis, he was
ﬁrst evaluated for an infectious process. The work-up,
including bacterial, fungal, and viral cultures, was nega-
tive. In regards to iatrogenic causes, he was not receiving
glucocorticoids or growth factor support. We also evalu-
ated his peripheral smear and performed a bone marrow
biopsy for evidence of marrow invasion by adenocarcinoma
or evidence of a primary hematologic malignancy (chronic
myelogenous leukemia or another myeloproliferative neo-
plasm), and we did not ﬁnd evidence of either process. His
peripheral smear on day 305, when his WBC count was
94,300/mm3 (96.1% PMN/bands), demonstrated a myeloid
cell left shift with mostly mature cells and no blasts. His
red blood cells were normochromic and normocytic. There
were dacrocytes, rare schistocytes and reticulocytopenia.
He had thrombocytosis with some large forms. His bone
marrow was hypercellular with trilineage hematopoiesis.
Flow cytometry demonstrated a predominance of T-cells
within the lymphoid gate. There was no increase in blasts,
aberrant marker expression, or evidence of a primary
hematologic neoplasm. Molecular PCR evaluation for the
JAK2 V617 mutation and BCR-ABL transcripts were both
negative.
Finally, after ruling out a primary bone marrow process
and marrow inﬁltration by NSCLC, we tested the patient's
serum for endogenous levels of granulocyte-monocyte col-
ony-stimulating factor (GM-CSF), G-CSF, interleukin-1 alpha(IL-1α) and interleukin-6 (IL-6). His serum GM-CSF and IL-1α
levels were normal, his serum IL-6 level was mildly elevated
at 10 pg/ml (0–5 pg/ml) and his serum G-CSF was signiﬁ-
cantly elevated at 507 pg/ml (0–39.1 pg/ml). These results
corresponded to a WBC count of 48,700/mm3 (Day 318). G-
CSF is produced by endothelium, macrophages and other
immune cells. Given that the WBC decreased in response to
tumor directed treatments, it is most likely that the bulk of
the identiﬁed G-CSF originated from tumor cells.
Finally, endobronchial tumor tissue (Figure 2a) was
assayed by immunohistochemistry (IHC) for G-SCF expres-
sion (anti-G-CSF antibody, clone 3D1, catalog number sc-
53292, Santa Cruz Biotechnology, Inc., Dallas, TX). Inﬁltrat-
ing tumor cells diffusely stained positive for G-CSF, while
surrounding normal tissue and controls were negative for G-
CSF staining (Figure 2b). Given these results he was
diagnosed with a PLR caused by tumor production of G-CSF.
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Prior studies have identiﬁed a causative relationship
between elevated WBC count and cytokines produced by
the tumor cells. Studies in cell lines, mouse models and
human tumor tissues have demonstrated that one possible
mechanism of G-CSF upregulation is through RAS/RAF/MEK
pathway activation. Currently, MEK inhibitors are an active
area of clinical development for use as cancer therapeutics
[6]. G-CSF has been demonstrated to be important for
granulocyte mobilization, possibly through expansion and
mobilization of CD11b+Gr1+ myeloid cells that produce
tumorigenic factors such as Bv8, matrix metalloproteinases,
and TGF-beta. Increases in this CD11b+Gr1+ myeloid cell
population may facilitate tumor cell invasion at sites of
metastasis [6,7]. This has primarily been demonstrated in
mice with breast cancer lung metastatses; however, ele-
vated levels of G-CSF-regulated myeloid cells and Bv8
expression in inﬁltrating neutrophils have been identiﬁed
in human lung adenocarcinoma, indicating that this may be
a more generalizable mechanism of metastasis [8,9].
Although much of this work has yet to be translated to
lung cancer, the case presented here and the increased
frequency of PLR in NSCLC compared with other cancers
provide a compelling justiﬁcation for investigation of this
pathway in lung cancer [4]. Additionally, given the mole-
cular pathways underlying PLR and the possible implications
for progression of disease, it may be reasonable to move
beyond using the WBC count (when not impacted by
myelosupressive or supportive treatments) as a prognostic
marker and investigate it and G-CSF as surrogate markers
for tumor cell death. This may allow treatment monitoring
at a molecular level, which current imaging modalities are
not able to provide.Disclosures
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